Browse Results

  • Division: : Cancer Center


There are 218 clinical trial(s) matching your criteria.

Back

A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects with Acute Graft-Versus-Host Disease with Lower Gastrointestinal Involvement

Investigator: Krishna Komanduri

Institutional Protocol #: 20160975

National Clinical Trials Identifier: NCT02956122

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II/III

Enrolling Since: 4/14/2017

C-700-01: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Investigator: Breelyn Wilky

Institutional Protocol #: 20170076

National Clinical Trials Identifier: NCT03104699

Division: Cancer Center

Therapeutic Area: Bone and Soft Tissue Cancers

Phase: Phase I/II

Enrolling Since: 4/10/2017

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

Investigator: Lazaros Lekakis

Institutional Protocol #: 20160645

National Clinical Trials Identifier: NCT02701634

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 2/3/2017

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).

Investigator: James Hoffman

Institutional Protocol #: 20160548

National Clinical Trials Identifier: NCT01863550

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 12/19/2016

Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia

Investigator: Ronan Swords

Institutional Protocol #: 20151147

National Clinical Trials Identifier: NCT02610777

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 7/11/2016

1138131 A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post- Polycythemic Myelofibrosis)

Investigator: Ronan Swords

Institutional Protocol #: 20151074

National Clinical Trials Identifier: NCT02530619

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 6/24/2016

Thyroid cancer and MMPs

Investigator: Sharon Elliot

Institutional Protocol #: 20057541

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Thyroid and Other Endocrine Cancers

Phase: N/A

Enrolling Since: 6/24/2008

Back